Outcomes
The primary outcome of this trial was the VEINES-QOL/Sym score at 12 months after the initial treatment.If the confidence interval for the difference in VEINES-QOL/Sym scores between SAP and TAP fell within the predetermined margin of 5 per cent of the TAP group’s VEINES-QOL/Sym score at 12 months’ follow-up, SAP could be considered non-inferior to TAP.Secondary outcomes were the proportion of patients in the SAP group who received additional treatment of the GSV/AASV, EQ-5D™ (including EQ-VAS) scores, patient satisfaction after treatment and perceived improvement, VCSS and anatomical success at 3- and 12-month follow-up, and cost-effectiveness.